People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Hospitals and Physicians, Biotechnology, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| U S HealthVest, LLC | — | Hospitals and Physicians | Series C | $125.3M | $212.6M | 2016 |
| Ignyta, Inc. | — | Biotechnology | Series C | $113.6M | $1.2B | 2013 |
| Proximie Ltd | — | Other | Series C | $75.0M | $896.6M | 2022 |
| Nexusbird, Inc | — | Other Technology | Series B | $60.1M | $281.1M | 2021 |
| SpecTrust, Inc. | — | Other Technology | Series A | $29.3M | $116.8M | 2021 |
| Affiniti Finance, Inc. | — | Other | Series B | $26.6M | $84.9M | 2025 |
| Bionomics Limited/Fi | — | Biotechnology | Series A | $10.4M | $376.3M | 2012 |
| Ignyta, Inc. | — | Other | Series A | $7.9M | $83.3M | 2011 |
| Eclipse Therapeutics, Inc. | — | Other | Seed | $2.8M | $51.6M | 2011 |
Jonathan Lim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Lim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Adams | 1 | 13 |
| Brian Chee | 1 | 10 |
| Stacey Bishop | 1 | 9 |
| Jon Lim | 1 | 9 |
| Scott Huennekens | 1 | 7 |
| Geoff Bernstein | 1 | 5 |
| Peter Chu | 1 | 3 |
| Christopher Reyes | 1 | 3 |
| Patrick O'Connor | 1 | 3 |
| Richard Kresch | 1 | 3 |
| Victor Wang | 1 | 3 |
| TIM EADES | 1 | 3 |
| Jonathan E. Lim, M.D. | 1 | 3 |
| Alexander Casdin | 1 | 2 |
| Mike Jennings | 1 | 2 |
| Zachary Hornby | 1 | 2 |
| Mike Viscuso | 1 | 2 |
| James Cha | 1 | 2 |
| Pratik S. Multani, M.D. | 1 | 2 |
| Deborah Rathjen | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.